There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BiomX (PHGE – Research Report), Quoin Pharmaceuticals (QNRX – Research Report) and Precigen (PGEN – Research Report) with bullish sentiments.
BiomX (PHGE)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on BiomX today and set a price target of $7.00. The company’s shares closed last Tuesday at $0.40.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BiomX with a $7.00 average price target.
See the top stocks recommended by analysts >>
Quoin Pharmaceuticals (QNRX)
Maxim Group analyst Naz Rahman reiterated a Buy rating on Quoin Pharmaceuticals yesterday and set a price target of $15.00. The company’s shares closed last Tuesday at $4.14, close to its 52-week low of $3.64.
According to TipRanks.com, Rahman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Quoin Pharmaceuticals is a Moderate Buy with an average price target of $15.00.
Precigen (PGEN)
Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Precigen on November 9 and set a price target of $7.00. The company’s shares closed last Tuesday at $0.89, close to its 52-week low of $0.81.
According to TipRanks.com, Burnett has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $9.00, representing an 899.7% upside. In a report issued on November 10, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PHGE:
- BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
- PHGE Upcoming Earnings Report: What to Expect?
- BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
- BiomX appoints Edward Williams to board of directors
- BiomX Announces the Appointment of Edward L. Williams to its Board of Directors
